Italia -
italiano -
Ministero della Salute
modulis 100 mg/ml soluzione orale
ceva salute animale s.p.a. - ciclosporina - ciclosporina - nd - ciclosporin
Italia -
italiano -
Ministero della Salute
dexacortone
le vet beheer b.v. - desametasone - desametasone - 0.5 milligrammo (i), desametasone - 2 milligrammo (i), desametasone - 0.5 mg, desametasone - 2 mg - dexamethasone
Italia -
italiano -
Ministero della Salute
librela
zoetis belgium sa - bedinvetmab - bedinvetmab - 5 mg, bedinvetmab - 10 mg, bedinvetmab - 30 mg, bedinvetmab - 15 mg, bedinvetmab - 20 mg - bedinvetmab
Italia -
italiano -
AIFA (Agenzia Italiana del Farmaco)
levobupivacaina molteni
l. molteni & c. dei f.lli alitti societa' di esercizio s.p.a. - levobupivacaina - levobupivacaina
Italia -
italiano -
AIFA (Agenzia Italiana del Farmaco)
levobupivacaina bioindustria l.i.m.
bioindustria laboratorio italiano medicinali s.p.a. - levobupivacaina - levobupivacaina
Italia -
italiano -
Ministero della Salute
stellamune mycoplasma
elanco gmbh - mycoplasma hyopneumoniae, inattivato - mycoplasma hyopneumoniae, inattivato - 6000 unit? elisa, mycoplasma hyopneumoniae; inattivato - 6000 unit? elisa, mycoplasma hyopneumoniae inattivato - 6000 u. elisa - mycoplasma
Unione Europea -
italiano -
EMA (European Medicines Agency)
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
Italia -
italiano -
Ministero della Salute
stellamune uno
eli lilly italia s.p.a. - mycoplasma hyopneumoniae inattivato - mycoplasma hyopneumoniae inattivato - nd log/10 u elisa - mycoplasma
Italia -
italiano -
Ministero della Salute
hyogen
ceva salute animale s.p.a. - mycoplasma hyopneumoniae - mycoplasma hyopneumoniae - nd - mycoplasma
Italia -
italiano -
Ministero della Salute
porsilis m hyo id once
intervet international b.v. - mycoplasma hyopneumoniae, ceppo 11, inattivato - mycoplasma hyopneumoniae, ceppo 11, inattivato - nd, mycoplasma hyopneumoniae; ceppo 11; inattivato - nd, mycoplasma hyopneumoniae inattivato - nd log/2 titolo ab, mycoplasma hyopneumoniae inattivato - 6.5 log/2 titolo ab - mycoplasma